skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

18 Total results for product and free and sample content found

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

Quick Listen: Scrip's Five Must-Know Things

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.

Topic cell-and-gene-therapy

In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース, Scrip: 世界の医...

Webinar: Is Biopharma Fit For the New Decade?

Webinar: Is Biopharma Fit For the New Decade?

Download your article pack now for a glimpse of some of the topics that will be covered by our panel of experts during the “Is Biopharma Fit for the New Decade?” webinar.

Topic Cell and gene therapy Policy and regulation

Adoptive Cell Therapy

Adoptive Cell Therapy

Citeline recently introduced a new Therapeutic Class called "Adoptive cell therapy", enabling more granular searching capabilities to hone in on this exciting cancer immunotherapy that is expanding the horizon of personalized medicine

Topic cell-and-gene-therapy

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

Datamonitor Healthcare's Top Research Reports

Datamonitor Healthcare's Top Research Reports

Pink Sheet: 世界の薬事規制と承認審査に関するニュース

Zolgensma Data Integrity Fallout

Zolgensma Data Integrity Fallout

Novartis finds itself facing possible criminal or civil action for admitted data manipulation on its application for Zolgensma, a gene therapy used to treat children with spinal muscular atrophy (SMA) – manipulation disclosed only after FDA approval. Pink Sheet was the first to report on the drug’s loss of EU accelerated assessment, nearly 3 weeks before the pharma giant admitted to submitting falsified data to FDA. Follow the scandal and anticipate its implications on the industry with Pink Sheet’s coverage and timeline.

Topic cell-and-gene-therapy fda

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

オンラインセミナー:NASH治療薬の展望と市場動向

オンラインセミナー:NASH治療薬の展望と市場動向

NASH(非アルコール性脂肪性肝炎)はさらに大きな流行病となりつつあり、あらゆる規模の企業が、業界初のNASH治療薬を市場に出すためにしのぎを削っています。新薬および転用された新薬探索、NASHの治療に関する詳細なディスカッション、およびこの分野のディールメイキング、ライセンスシング、提携戦略についてお聞きください。

Topic cell-and-gene-therapy drug-development-landscape drug-approval

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain

Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain

Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.

Topic cell-and-gene-therapy drug-development-landscape

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

Payers Must Brace For Coming Wave Of Cell And Gene Therapies

Payers Must Brace For Coming Wave Of Cell And Gene Therapies

One regenerative medicine for an ultra-rare disease may have a small impact, but payers will be flooded with dozens of new cell and gene therapies over the next few years. Enzyvant, Novartis and Spark share how they are positioning their complex products.

Topic Cell and gene therapy

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

Webinar: Manufacturing Challenges Facing Cell and Gene Therapy

As more regenerative medicine products approach clinical testing and commercialization, seize this opportunity to hear detailed insights and industry best practices from preeminent sector experts. You’ll gain a deep understanding of numerous nurdles unique to bringing durable, curative therapies to patients in need.

Topic cell-and-gene-therapy

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。